P Merville
Overview
Explore the profile of P Merville including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
864
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rostaing L, Hertig A, Albano L, Anglicheau D, Durrbach A, Vuiblet V, et al.
Am J Transplant
. 2015 Mar;
15(5):1303-12.
PMID: 25808994
Markers of epithelial-mesenchymal transition (EMT) may identify patients at high risk of graft fibrogenesis who could benefit from early calcineurin inhibitor (CNI) withdrawal. In a randomized, open-label, 12-month trial, de...
12.
Hellemans R, Hazzan M, Durand D, Mourad G, Lang P, Kessler M, et al.
Am J Transplant
. 2015 Feb;
15(7):1923-32.
PMID: 25707875
We previously reported a randomized controlled trial in which 227 de novo deceased-donor kidney transplant recipients were randomized to rabbit antithymocyte (rATG, Thymoglobulin) or daclizumab if they were considered to...
13.
Thierry A, Mourad G, Buchler M, Choukroun G, Toupance O, Kamar N, et al.
J Transplant
. 2014 May;
2014:171898.
PMID: 24829794
In a six-month, multicenter, open-label trial, de novo kidney transplant recipients at low immunological risk were randomized to steroid avoidance or steroid withdrawal with IL-2 receptor antibody (IL-2RA) induction, enteric-coated...
14.
Chauvet C, Chauveau P, Hourmant M, Hurault de Ligny B, Kolko A, Lefrancois G, et al.
Nephrol Ther
. 2013 Nov;
9(7):459-60.
PMID: 24176652
No abstract available.
15.
Taton B, Moreau K, Lepreux S, Bachelet T, Trimoulet P, de Ledinghen V, et al.
Transpl Infect Dis
. 2013 Oct;
15(6):E211-5.
PMID: 24103101
Hepatitis E virus (HEV) has been identified as a cause of chronic viral hepatitis in immunocompromised patients. Some glomerular diseases were found to be associated with this infection. We report...
16.
Bachelet T, Couzi L, Lepreux S, Legeret M, Pariscoat G, Guidicelli G, et al.
Am J Transplant
. 2013 Oct;
13(11):2855-64.
PMID: 24102857
Allograft pathology, antibody-tissue interaction as demonstrated by C4d deposition and serological evidence of donor-specific antibodies (DSA) are the cardinal diagnostic features of antibody-mediated lesions (AML) in kidney transplantation. However, discrepancy...
17.
Couzi L, Helou S, Bachelet T, Martin S, Moreau K, Morel D, et al.
Transplant Proc
. 2012 Nov;
44(9):2809-13.
PMID: 23146529
International consensus guidelines on the management of cytomegalovirus (CMV) infections in kidney transplantation recommend the use of universal prophylaxis over preemptive therapy for the highest risk kidney transplant recipients (KTR),...
18.
Carrie C, Quinart A, Gille O, Merville P, Sztark F
Ann Fr Anesth Reanim
. 2011 Nov;
30(12):939-41.
PMID: 22040864
No abstract available.
19.
Couzi L, Helou S, Bachelet T, Moreau K, Martin S, Morel D, et al.
Am J Transplant
. 2011 Oct;
12(1):202-9.
PMID: 21967659
Anti-cytomegalovirus (CMV) prophylaxis is recommended in D+R- kidney transplant recipients (KTR), but is associated with a theoretical increased risk of developing anti-CMV drug resistance. This hypothesis was retested in this...
20.
Bachelet T, Couzi L, Guidicelli G, Moreau K, Morel D, Merville P, et al.
Am J Transplant
. 2011 Jun;
11(7):1543-4.
PMID: 21668642
No abstract available.